Alnylam Pharmaceuticals’ (ALNY) “Buy” Rating Reaffirmed at Chardan Capital

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reaffirmed by analysts at Chardan Capital in a report released on Friday,Benzinga reports. They currently have a $300.00 price objective on the biopharmaceutical company’s stock. Chardan Capital’s price target indicates a potential upside of 18.30% from the stock’s current price.

Other equities analysts have also issued research reports about the company. StockNews.com lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Bank of America lifted their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a research note on Friday. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. Needham & Company LLC reiterated a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Finally, HC Wainwright lifted their price objective on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a report on Monday, February 24th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $304.74.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $253.60 on Friday. The firm has a market capitalization of $32.83 billion, a price-to-earnings ratio of -116.87 and a beta of 0.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The business has a fifty day moving average of $256.25 and a 200 day moving average of $259.51. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, research analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the sale, the chief executive officer now owns 81,526 shares of the company’s stock, valued at $20,802,989.42. The trade was a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Phillip A. Sharp sold 11,250 shares of the business’s stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

Large investors have recently modified their holdings of the stock. Capital World Investors grew its stake in shares of Alnylam Pharmaceuticals by 0.6% during the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company’s stock worth $3,906,284,000 after purchasing an additional 92,101 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Alnylam Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company’s stock worth $2,996,296,000 after purchasing an additional 98,303 shares in the last quarter. Capital Research Global Investors grew its stake in shares of Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock worth $1,639,767,000 after purchasing an additional 1,724,610 shares in the last quarter. Regeneron Pharmaceuticals Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 39.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company’s stock worth $1,031,705,000 after purchasing an additional 1,245,195 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.